Dr. James A. Fagin

Cancer Treated:

530 East 74th Street New York NY 10021
646-608-2921

Dr. Fagin leads the Division of Subspecialty Medicine at Memorial Sloan Kettering Cancer Center, where he integrates laboratory discovery with direct patient care to improve outcomes for endocrine malignancies. His laboratory uncovered how BRAF and RAS mutations rewire thyroid-cell signaling, findings that inspired clinical trials of MEK inhibitors to restore radioiodine uptake in metastatic disease. He coordinates a multidisciplinary team that spans basic science, radiochemistry, and nuclear medicine, ensuring that genomic insights translate quickly to first-in-human studies such as the ASTRA adjuvant selumetinib protocol.

 

International societies rely on Dr. Fagin’s scholarship to refine guidelines on diagnostic imaging, dynamic risk stratification, and targeted therapy sequencing. The American Thyroid Association awarded him the John B. Stanbury Medal for pathophysiology research, citing his work on MAP-kinase suppression and redifferentiation. The Endocrine Society honored him with the Outstanding Clinical Investigator Laureate Award for sustained contributions that link molecular mechanisms to therapeutic innovation. He serves on editorial boards for Journal of Clinical Endocrinology & Metabolism and Cancer Discovery, mentoring fellows on rigorous trial design and responsible data sharing.

 

Current investigations examine how sustained ERK blockade re-expresses thyroid-specific genes and sensitizes tumors to radioligand therapy. Parallel efforts explore RET and NTRK fusions, with basket trials evaluating selective inhibitors in rare thyroid variants. Through global consortium leadership he advocates equitable access to molecular testing, emphasizing that precision medicine must accompany survivorship resources addressing fatigue, bone health, and emotional well-being.

Book An Appointment